Evan Weber

We are experiencing an assault on science unparalleled by anything I’ve seen in my life. It’s not one issue or another anymore, the entire institution is under attack by the most powerful individuals in the country.

This Friday, where will you be?

standupforscience2025.org

Any speculation why big pharma and biotech industries have been so quiet about the current defunding of biomedical research?

(which also means the defunding of biomedical research training)

With an Ro of 12-18, a mortality rate of about 1-2/10,000 and an MMR vaccination rate in this area of Texas at 82% we should expect to see this expand to many 1000 cases quickly and, unfortunately, potential deaths.

BrainChild-03 Trial Supports Safety of B7-H3 CAR T-cell Therapy for DIPG Main Finding: A phase I trial supported the safety and feasibility of repeated intracranial infusions of B7-H3 CAR T cells for DIPG.Concept: B7-H3 is an immunoregulatory protein expressed on the surfa...

Honored to have our recently published first-in-human phase 1 clinical trial of repeatedly dosed intracerebroventrocular B7-H3 #CARTcells for children with #DIPG highlighted in @theaacr.bsky.social and #CancerDiscovery Research Watch ❤️🔬

My weekend with immunologists devising new strategies to treat cancer, allergy, Alzheimer’s, autoimmunity and infection. The WH has just paused peer-reviewed NIH funding that pays for these studies. If you care about human life, write your representatives. Demand that NIH funding is restored asap.

Super cool, congrats Lukasz!

Excited and grateful that our initial report on temperature-sensitive protein switches is now published
@naturemethods.bsky.social Co-led by PhD students Will Benman and @dennishuang.bsky.social

www.nature.com/articles/s41...

Brief thread:

Starting off 2025 inspired by this fantastic interview with @geochurch.bsky.social

Beyond George's intellect and scientific genius, he is so adept at communicating complex ideas about teamwork, creativity, discovery, and innovation. Thanks @nightsciencepod.bsky.social @itaiyanai.bsky.social!

I’m excited to be a co-organizer this year for the SITC Winter School, where we focus on the core principles of #TumorImmunology & #CancerImmunotherapy. We’ll also be discussing advancements in drug development, biomarkers, & clinical trials. More info here: go.sitcancer.org/3XOCoBh Please join us!

Calling all cell therapists!

The SITC Spring Scientific on Cellular Therapy for Solid Tumors takes place March 12-14 2025 in sunny San Diego. Fantastic speaker lineup, and slots for abstract talks

www.sitcancer.org/education/sp...

Early registration deadline is THIS FRIDAY. Abstracts due Jan 8th.

Congrats, can’t wait to read!

Nutrient-driven histone code determines exhausted CD8+ T cell fates ACLY-deficient CAR T cells targeting the tumor-associated antigen disialoganglioside GD2 (GD2 CAR T cells) also resisted acquiring TEX-like properties, exhibiting reduced CD39 expression when co-cultu...

Here is link to Shixin's new paper: www.science.org/doi/epdf/10....

Fascinating study where they label CAR T cells and follow their trafficking in patients! Immediate biodistribution is to the liver and spleen, and they can see whether the Car goes into extramedullary masses. What explains differences between patients?

EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function
www.cell.com/cancer-cell/...

Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results - Nature Medicine Preliminary findings in seven patients with mismatch repair-proficient metastatic colorectal cancer who were treated in the context of a phase 2 trial show that adoptive transfer of autologous periphe...

ICYMI - over the summer Maria Parkhurst from our branch published one of the first reports of clinical responses after adoptive cell transfer of TCR engineered private neoantigen (tumor mutation) targeting T cells in metastatic cancer patients 🧪🦠🔬🩺 1/3 #Immunosky
www.nature.com/articles/s41...

TET2 regulates early and late transitions in exhausted CD8+ T cell differentiation and limits CAR T cell function Modulation of exhausted CD8+ T cell differentiation by targeting TET2 improves therapeutic potential of CAR T cells in cancer.

🚨NEW🧪: TET2 regulates early and late transitions in exhausted CD8+ T cell differentiation and limits CAR T cell function - #CARTCell #immunotherapy #TCell #tcellrx #immunology www.science.org/doi/10.1126/...

Postdocs in Immuno-Oncology: consider this awesome career development opportunity! You get to network with accomplished faculty and rising start peers in preparation for running a research group!
Info: irvingcancerimmunologysymposium.com
Application link: docs.google.com/forms/d/e/1F...

In vivo CRISPR screens identify key modifiers of CAR T cell function in myeloma https://www.biorxiv.org/content/10.1101/2024.11.19.624352v1 Chimeric antigen receptor (CAR) T cells are highly effective in hematologic malignancies. However, l

In vivo CRISPR screens identify key modifiers of CAR T cell function in myeloma https://www.biorxiv.org/content/10.1101/2024.11.19.624352v1

I made a starter pack for those of us interested in or working on T cells. Let me know if you would like to be added or know somebody that should be added.

Looking forward to scientific discussions and updates on our favorite immune cell type!

Inspired by the other amazing starter packs - here's one for cancer researchers!

I tried to make this broad - from immunology to genomics to cell biology and so much more..

This list also includes organizations & institutes supporting cancer researchers 🧪🔬⚕️🩺

Hope its useful!

go.bsky.app/FEoaJMc

Sky Follower Bridge - Chrome Web Store Instantly find and follow the same users from your Twitter follows on Bluesky.

🐦➡️🦋 Looking to rebuild your network on Bluesky by reconnecting with your existing X/Twitter contacts? The Skylink browser extension makes it easy!
chromewebstore.google.com/detail/sky-f...

Thanks @jmschreiber91.bsky.social!
#scicomm #cancer #tumorimmunology